Change - Announcement of Cessation::RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

Issuer & Securities

Issuer/ Manager
BIOLIDICS LIMITED
Securities
BIOLIDICS LIMITED - SGXE89830751 - 8YY
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Cessation
Date &Time of Broadcast
14-Jun-2024 22:09:01
Status
New
Announcement Sub Title
RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER
Announcement Reference
SG240614OTHRSMGA
Submitted By (Co./ Ind. Name)
Zhu Hua
Designation
Executive Director and Chairman
Description (Please provide a detailed description of the event in the box below)
Resignation of Mr Song Tang Yih ("Mr Song") as an Executive Director and Chief Executive Officer ("CEO") of Biolidics Limited (the "Company").

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, Evolve Capital Advisory Private Limited (the "Sponsor") for compliance with relevant rules of the Singapore Exchange Securities Trading Limited ("SGX-ST").

This announcement has not been examined or approved by the SGX-ST, and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The details of the contact person for the Sponsor are: -

Name: Mr. Jerry Chua (Registered Professional, Evolve Capital Advisory Private Limited) and Mr. Tan Jun Yong (Registered Professional, Evolve Capital Advisory Private Limited)
Address :138 Robinson Road, Oxley Tower, #13-02, Singapore 068906
Tel :(65) 6241 6626

Additional Details

Name Of Person
Song Tang Yih
Age
60
Is effective date of cessation known?
Yes
If yes, please provide the date
30/06/2024
Detailed Reason (s) for cessation
To pursue other career opportunities.

The Sponsor, after having interviewed Mr Song, is satisfied that save as disclosed in this announcement, there is no other material reason for the resignation of Mr Song as an Executive Director and CEO of the Company.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?
No
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?
No
Any other relevant information to be provided to shareholders of the listed issuer?
No
Date of Appointment to current position
01/09/2021
Does the AC have a minimum of 3 members (taking into account this cessation)?
Yes
Number of Independent Directors currently resident in Singapore (taking into account this cessation)
2
Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months
2
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Executive Director and Chief Executive Officer
Role and responsibilities
Mr Song is responsible for the overall management, operations, strategic planning and business development of the Group.
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
None
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
24,501,500 shares in the Company
Past (for the last 5 years)
1. ClearCell Pte. Ltd.
2. Biomedics Laboratory Pte. Ltd.
Present
1. Drukpa Singapore Limited